Denosumab in the treatment of osteoporosis associated with chronic kidney disease
Osteoporosis is a substantial health concern worldwide, particularly among individuals with advanced chronic kidney disease (CKD). In this population, bone fragility is a prevalent complication attributable to disruptions in mineral and hormonal equilibria, leading to a non-vertebral-fracture risk that is 4 to 6 times higher than that of matched control individuals.1